The patent cliff isn’t a cliff. It’s a calendar.
Most pharma teams treat the “patent cliff” like weather—something that happens to you. But the companies winning the next cycle are treating it like a campaign: planned, staged, and executed with payer…

🚨 AI just hit the drug patent wall—and it didn’t slow down.
OpenAI’s GPT is being credited with a breakthrough in how quickly and effectively teams can navigate the thicket of drug patents and related filings—reportedly delivering up to 70% faster “…

Predict the Attack: How to Forecast Paragraph IV Drug Patent Challenges—and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—through filings.
Paragraph IV patent challenge…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know exactly what you’re really buying.
If you’re launching a branded product—or defending one—you already know the headline: patent term matters. But in the …

Your competitor isn’t “innovating.” They’re extending. Here are 4 signals to watch.
In pharma, the most expensive word isn’t patent—it’s delay.
When a drug’s exclusivity horizon starts to shrink, competitors rarely stand still. They don’t always launch…

Biopharma teams don’t lose deals because they lack ambition. They lose because timing is misaligned.
In licensing, partnering, and BD strategy, the “pitch” is rarely just a pitch. It’s a calendar—built on patent life, regulatory milestones, and the ung…

OpenAI’s “GPT for life sciences” is getting the headlines—but the real question for drug developers isn’t what it can do in a demo. It’s what it changes in the messy, expensive, failure-prone reality of drug development.
That’s the subtext behind the l…